MDM4 is a key therapeutic target in cutaneous melanoma
Agnieszka Gembarska, Flavie Luciani, Clare Fedele, Elisabeth A Russell, Michael Dewaele, Stephanie Villar, Aleksandra Zwolinska, Sue Haupt, Job de Lange, Dana Yip, James Goydos, Jody J Haigh, Ygal Haupt, Lionel Larue, Aart Jochemsen, Hubing Shi, Gatien Moriceau, Roger S Lo, Ghanem Ghanem, Mark Shackleton Show all
NATURE MEDICINE | NATURE PUBLISHING GROUP | Published : 2012
Related Projects (3)
Awarded by Australian National Health and Medical Research Council
We thank O.Van Goethem for excellent technical assistance. We thank P. Agostinis, P. Wolter and M. Skipper for helpful discussions and comments on the manuscript. We thank M. Cario-Andre and A. Taied for materials from human nevi. A. Zwolinska is a recipient of a 'Het Fonds Wetenschappelijk Onderzoek-Vlaanderen (FWO)' scholarship. C. Fedele was supported by a Clare Oliver Memorial Fellowship from the Victorian Cancer Agency. M. Shackleton was supported by fellowships from Pfizer Australia and the Victorian Endowment for Science, Knowledge and Innovation (VESKI). Y. and S. Haupt were supported by the Australian National Health and Medical Research Council (nos. 509197, 1026990 and 628426) and VESKI. R.S. Lo was supported by Stand Up to Cancer, the Joint Center for Translational Medicine, the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research, and the Seaver Institute. This work was supported by the Intramural Research Program of the US National Institutes of Health and the National Cancer Institute, the Association for International Cancer Research (AICR), the Melbourne Melanoma Project, the Victorian Cancer Agency and the 'Belgian Foundation against Cancer'.